Ipatasertib
- Generic Name
- Ipatasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32ClN5O2
- CAS Number
- 1001264-89-6
- Unique Ingredient Identifier
- 524Y3IB4HQ
- Background
Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
CRAFT: The NCT-PMO-1602 Phase II Trial
- Conditions
- Metastatic or Locally Advanced Malignancies
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- German Cancer Research Center
- Target Recruit Count
- 72
- Registration Number
- NCT04551521
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Germany
🇩🇪Universitätsklinikum Freiburg, Freiburg, Germany
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: CapecitabineDrug: AtezolizumabDrug: Ribociclib (dose #1)Drug: Inavolisib (dose #2)Drug: AbemaciclibDrug: Trastuzumab DeruxtecanDrug: IpatasertibDrug: Sacituzumab GovitecanDrug: FulvestrantDrug: Ribociclib (dose #2)Drug: Inavolisib (dose #1)Drug: SGN-LIV1ADrug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)Drug: TocilizumabDrug: BevacizumabDrug: LetrozoleDrug: Nab-PaclitaxelDrug: InavolisibDrug: Selicrelumab
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 580
- Registration Number
- NCT03424005
- Locations
- 🇺🇸
University of California San Diego Medical Center, La Jolla, California, United States
🇺🇸Hackensack Univ Medical Center, Hackensack, New Jersey, United States
🇺🇸NYU Langone Medical Center, New York, New York, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Advanced Malignant Solid NeoplasmBreast CarcinomaCervical CarcinomaLiver CarcinomaMalignant Uterine NeoplasmRecurrent Gastric CarcinomaRecurrent Head and Neck CarcinomaRecurrent Ovarian CarcinomaRecurrent Prostate CarcinomaRecurrent Rectal Carcinoma
- Interventions
- Drug: AfatinibDrug: BinimetinibDrug: AdavosertibDrug: CapivasertibDrug: Afatinib DimaleateProcedure: Biospecimen CollectionOther: Cytology Specimen Collection ProcedureDrug: DabrafenibDrug: FexagratinibDrug: DasatinibDrug: IpatasertibDrug: DefactinibDrug: SapanisertibProcedure: BiopsyDrug: CrizotinibDrug: Dabrafenib MesylateDrug: PI3K-beta Inhibitor GSK2636771Drug: Defactinib HydrochlorideDrug: PalbociclibBiological: NivolumabDrug: CopanlisibDrug: TaselisibDrug: UlixertinibDrug: Copanlisib HydrochlorideBiological: Trastuzumab EmtansineBiological: RelatlimabProcedure: Computed TomographyDrug: TrametinibBiological: PertuzumabDrug: ErdafitinibProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanDrug: LarotrectinibDrug: Larotrectinib SulfateProcedure: EchocardiographyDrug: OsimertinibBiological: TrastuzumabOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingDrug: VismodegibDrug: Sunitinib MalateProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Thomas Hospital, Fairhope, Alabama, United States
🇺🇸Mobile Infirmary Medical Center, Mobile, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.